Optimizing Patient Care in Hepatic Encephalopathy

Arun Jesudian, MD; Ralph J. Riello, PharmD, BCPS, and Chas McCormick, RPh, MBA, delve into the complexities of hepatic encephalopathy, exploring the various risk factors that contribute to its development, such as alcohol-induced cirrhosis, sarcopenia, CNS medications, opioids, and other potential triggers.

Medical experts examine the current treatment landscape and goals for patients with hepatic encephalopathy, addressing patient outcomes and hospital discharge planning, while also acknowledging that some patients may require rehabilitation or long-term care facilities to sustain remission and optimize their recovery.

Panelists explore the critical roles of lactulose and rifaximin in managing hepatic encephalopathy, a potentially severe condition that can lead to intensive care unit (ICU) admission.

Arun Jesudian, MD; Ralph J. Riello, PharmD, BCPS, and Chas McCormick, RPh, MBA, highlight the importance of adhering to evidence-based guidelines and utilizing approved medications in the management of hepatic encephalopathy, emphasizing their crucial role in preventing patient relapse within 30 days of hospital discharge.